Market closedNon-fractional
Rhythm Pharmaceuticals/RYTM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
Ticker
RYTM
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Boston, United States
Employees
226
Website
rhythmtx.com
RYTM Metrics
BasicAdvanced
$3B
Market cap
-
P/E ratio
-$4.68
EPS
2.04
Beta
-
Dividend rate
Price and volume
Market cap
$3B
Beta
2.04
Financial strength
Current ratio
4.353
Quick ratio
3.986
Long term debt to equity
174.814
Total debt to equity
176.101
Interest coverage (TTM)
-17.43%
Management effectiveness
Return on assets (TTM)
-56.20%
Return on equity (TTM)
-194.69%
Valuation
Price to revenue (TTM)
31.588
Price to book
49.09
Price to tangible book (TTM)
55.2
Price to free cash flow (TTM)
-15.989
Growth
Revenue change (TTM)
173.52%
Earnings per share change (TTM)
39.22%
3-year revenue growth (CAGR)
1,279.72%
3-year earnings per share growth (CAGR)
55.40%
What the Analysts think about RYTM
Analyst Ratings
Majority rating from 9 analysts.
RYTM Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$26M
7.02%
Net income
-$141M
239.66%
Profit margin
-545.55%
217.36%
RYTM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.82
-$0.76
-$0.70
-$2.35
-
Expected
-$0.79
-$0.74
-$0.70
-$2.16
-$0.71
Surprise
3.16%
2.78%
0.29%
8.68%
-
RYTM News
AllArticlesVideos
Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
GlobeNewsWire·4 days ago
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
GlobeNewsWire·2 weeks ago
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rhythm Pharmaceuticals stock?
Rhythm Pharmaceuticals (RYTM) has a market cap of $3B as of July 27, 2024.
What is the P/E ratio for Rhythm Pharmaceuticals stock?
The price to earnings (P/E) ratio for Rhythm Pharmaceuticals (RYTM) stock is 0 as of July 27, 2024.
Does Rhythm Pharmaceuticals stock pay dividends?
No, Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Rhythm Pharmaceuticals dividend payment date?
Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders.
What is the beta indicator for Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals (RYTM) has a beta rating of 2.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Rhythm Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.